Shuntai Zhou 1, Collin S Hill 1, Sanjay Sarkar 2, Longping V Tse 3, Blaide M D Woodburn 1 4, Raymond F Schinazi 5, Timothy P Sheahan 3, Ralph S Baric 3 6, Mark T Heise 2 6, Ronald Swanstrom 1 7
Affiliations Expand
- PMID: 33961695
- PMCID: PMC8136050
- DOI: 10.1093/infdis/jiab247
Abstract
Mutagenic ribonucleosides can act as broad-based antiviral agents. They are metabolized to the active ribonucleoside triphosphate form and concentrate in genomes of RNA viruses during viral replication. β-d-N4-hydroxycytidine (NHC, initial metabolite of molnupiravir) is >100-fold more active than ribavirin or favipiravir against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with antiviral activity correlated to the level of mutagenesis in virion RNA. However, NHC also displays host mutational activity in an animal cell culture assay, consistent with RNA and DNA precursors sharing a common intermediate of a ribonucleoside diphosphate. These results indicate highly active mutagenic ribonucleosides may hold risk for the host.
Keywords: NHC; SARS-CoV-2; molnupiravir; mutagenicity.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
